The severity of the metabolic syndrome increases over time within individuals, independent of baseline metabolic syndrome status and medication use: The Atherosclerosis Risk in Communities Study

Atherosclerosis

Volumn 243, Issue 1, 2015, Pages 278-285

  Vishnu, Abhishek ^a   Gurka, Matthew J ^a   DeBoer, Mark D ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cardiovascular disease; Metabolic syndrome x; Minority health; Type 2 diabetes mellitus

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; AGE; ARTICLE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG USE; DYSLIPIDEMIA; ETHNICITY; FEMALE; FOLLOW UP; GENDER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SCORING SYSTEM; AFRICAN AMERICAN; AGED; ATHEROSCLEROSIS; CAUCASIAN; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; ETHNIC GROUP; ETHNOLOGY; MIDDLE AGED; PREVALENCE; SEVERITY OF ILLNESS INDEX;

AFRICAN AMERICANS; AGED; ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; SEVERITY OF ILLNESS INDEX;

EID: 84942279436     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.09.025     Document Type: Article

References (35)

1. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288(21):2709-2716.
2. Chen W., Srinivasan S.R., Li S., Xu J., Berenson G.S. Clustering of long-term trends in metabolic syndrome variables from childhood to adulthood in Blacks and Whites: the bogalusa heart study. Am. J. Epidemiol. 2007, 166(5):527-533. 10.1093/aje/kwm105.
3. Wilson P.W., D'Agostino R.B., Parise H., Sullivan L., Meigs J.B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112(20):3066-3072. 10.1161/CIRCULATIONAHA.105.539528.
4. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome - an American heart Association/National Heart, Lung, and Blood Institute Scientific statement. Circulation 2005, 112(17):2735-2752. 10.1161/circulationaha.105.169404.
5. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002, 346(6):393-403.
6. Beltran-Sanchez H., Harhay M.O., Harhay M.M., McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J. Am. Coll. Cardiol. 2013, 62(8):697-703. 10.1016/j.jacc.2013.05.064.
7. Goodman E., Daniels S.R., Meigs J.B., Dolan L.M. Instability in the diagnosis of metabolic syndrome in adolescents. Circulation 2007, 115(17):2316-2322. 10.1161/CIRCULATIONAHA.106.669994.
8. Kahn R., Buse J., Ferrannini E., Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 2005, 28(9):2289-2304.
9. Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., Heymsfield S.B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third national health and nutrition examination survey, 1988-1994. Arch. Intern. Med. 2003, 163(4):427-436.
10. Walker S.E., Gurka M.J., Oliver M.N., Johns D.W., DeBoer M.D. Racial/ethnic discrepancies in the metabolic syndrome begin in childhood and persist after adjustment for environmental factors. Nutr. Metab. Cardiovasc. Dis. 2012, 22(2):141-148. 10.1016/j.numecd.2010.05.006.
11. Anuurad E., Chiem A., Pearson T.A., Berglund L. Metabolic syndrome components in african-americans and European-American patients and its relation to coronary artery disease. Am. J. Cardiol. 2007, 100(5):830-834. 10.1016/j.amjcard.2007.04.025.
12. DeBoer M.D., Gurka M.J. Low sensitivity for the metabolic syndrome to detect uric acid elevations in females and non-Hispanic-black male adolescents: an analysis of NHANES 1999-2006. Atherosclerosis 2012, 220(2):575-580. 10.1016/j.atherosclerosis.2011.11.033.
13. DeBoer M.D., Dong L., Gurka M.J. Racial/ethnic and sex Differences in the ability of metabolic syndrome criteria to predict elevations in fasting insulin levels in adolescents. J. Pediatr. 2011, 159(6):975-981. U141. 10.1016/j.jpeds.2011.05.023.
14. Cowie C.C., Rust K.F., Byrd-Holt D.D., et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 2010, 33(3):562-568. 10.2337/dc09-1524.
15. Mensah G.A., Mokdad A.H., Ford E.S., Greenlund K.J., Croft J.B. State of disparities in cardiovascular health in the United States. Circulation 2005, 111(10):1233-1241.
16. Patel A., Huang K.C., Janus E.D., et al. Is a single definition of the metabolic syndrome appropriate?-A comparative study of the USA and Asia. Atherosclerosis 2006, 184(1):225-232. 10.1016/j.atherosclerosis.2005.04.012.
17. Gurka M.J., Lilly C.L., Norman O.M., DeBoer M.D. An examination of sex and racial/ethnic differences in the metabolic syndrome among adults: a confirmatory factor analysis and a resulting continuous severity score. Metabolism 2014, 63(2):218-225.
18. Gurka M.J., Ice C.L., Sun S.S., DeBoer M.D. A confirmatory factor analysis of the metabolic syndrome in adolescents: an examination of sex and racial/ethnic differences. Cardiovasc. Diabetol. 2012, 11. 10.1186/1475-2840-11-128.
19. DeBoer M.D., Gurka M.J., Woo J.G., Morrison J.A. Severity of metabolic syndrome as a predictor of cardiovascular disease between childhood and adulthood: the princeton lipid research cohort study. J. Am. Coll. Cardiol. 2015, 66(6):755-757. 10.1016/j.jacc.2015.05.061.
20. DeBoer M.D., G M.J., Woo J.G., Morrison J.A. Severity of metabolic syndrome as a predictor of type 2 diabetes between childhood and adulthood: the princeton lipid research cohort study. Diabetologia 2015, in press. 10.1007/s00125-015-3759-5.
21. The Atherosclerosis Risk in Communities (ARIC) Study design and objectives. The ARIC investigators. Am. J. Epidemiol. 1989, 129(4):687-702.
22. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001, 104(10):1108-1113.
23. Folsom A.R., Szklo M., Stevens J., Liao F., Smith R., Eckfeldt J.H. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 1997, 20(6):935-942.
24. McNeill A.M., Schmidt M.I., Rosamond W.D., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005, 28(2):385-390. 10.2337/diacare.28.2.385.
25. Baecke J.A., Burema J., Frijters J.E. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am. J. Clin. Nutr. 1982, 36(5):936-942.
26. Dekker J.M., Girman C., Rhodes T., et al. Metabolic syndrome and 10-year cardiovascular disease risk in the hoorn study. Circulation 2005, 112(5):666-673.
27. Hanley A.J., Karter A.J., Williams K., et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Circulation 2005, 112(24):3713-3721. 10.1161/CIRCULATIONAHA.105.559633.
28. Cowie C.C., Rust K.F., Byrd-Holt D.D., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: national health and nutrition examination survey 1999-2002. Diabetes Care 2006, 29(6):1263-1268.
29. Narayan K.M., Boyle J.P., Thompson T.J., Sorensen S.W., Williamson D.F. Lifetime risk for diabetes mellitus in the United States. JAMA 2003, 290(14):1884-1890.
30. Mozaffarian D., Benjamin E.J., Go A.S., et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015, 131(4):e29-322. 10.1161/CIR.0000000000000152.
31. Yeboah J., McClelland R.L., Polonsky T.S., et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012, 308(8):788-795. 10.1001/jama.2012.9624.
32. Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326(7404):1427. 10.1136/bmj.326.7404.1427.
33. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N. Engl. J. Med. 1996, 335(14):1001-1009. 10.1056/NEJM199610033351401.
34. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 2003, 92(2):152-160.
35. Knopp R.H. Drug treatment of lipid disorders. N. Engl. J. Med. 1999, 341(7):498-511. 10.1056/NEJM199908123410707.